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Abstract
OBJECTIVE: To investigate the effects of cinnamal-
dehyde (CA), an active and major compound in cin-
namon, on glucose metabolism and insulin resis-
tance in C57BLKS/J db/db mice.
METHODS: Sixteen male C57BLKS db/db mice
were randomly divided into control and CA treat-
ment groups. CA was given (20 mg·kg–1·day–1, p.
o.) for 4 weeks. Pure water was given to control and
db/+ mice. Subsequently, the levels of fasting
blood glucose (FBG), fasting serum insulin, triglyer-
ide, cholesterol, low-density lipoprotein -cholester-
ol (LDL-C), high-density lipoprotein-cholesterol
(HDL-C), and free fatty acids (FFA), as well as the
mRNA content of adiponectin and tumor necrosis
factor (TNF)-α in adipose tissue, glucose transport-
er type 4 (GLUT-4) in skeletal muscle, and protein
expressions of Akt, phospho-Akt (Thr308), AMPKα,
phospho-AMPKα (Thr172) in skeletal muscle were
measured.
RESULTS: 1) CA decreased serum levels of FBG and
insulin as well as body weight in db/db mice; 2) CA
increased serum HDL-C levels; 3) CA significantly
decreased the mRNA expression of TNF-α in adi-
pose tissue and upregulated mRNA expression of
GLUT-4 in skeletal muscle; 4) protein expression of
p-Akt was increased in CA-treated mice, but Akt,
AMPKα and p-AMPKα showed no change.
CONCLUSION: CA has antihyperglycemic and anti-
hyperlipidemic actions in db/db mice and could be
useful in the treatment of type-2 diabetes.
© 2012 JTCM. All rights reserved.
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INTRODUCTION
Type-2 diabetes mellitus (T2DM) is a chronic metabol-
ic disorder known to have affected »4% of adults aged ≥
20 years in 1995, and is expected to affect 380 million
by 2025.1 The cause of T2DM is not known, although
genetic and environmental factors (e.g. obesity, lack of
exercise) appear to play a part. T2DM occurs if the
pancreas does not produce sufficient amounts of insu-
lin or if the body cannot effectively use the insulin it
produces.2 Insulin resistance is a major contributor to
the pathogenesis of T2DM and has a key role in associ-
ated metabolic abnormalities such as hyperlipidemia
and hypertension.3
Several types of anti-diabetic medicines have been stud-
ied for their ability to lower blood glucose and ulti-
mately lower the prevalence of secondary complica-
tions of this disease. There is growing interest in folk
remedies using herbs due to the side effects associated
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with the synthetic medicines used in the treatment of
T2DM. Cinnamon is the bark of Cinnamomi cassise
(Lauraceae). It is a traditional folk medicine used in
China, Korea and Russia for the treatment of T2DM.4
Interest in this herb has increased since the discovery of
its potential effects on insulin5 and its ability to reduce
levels of fasting blood glucose (FBG) and plasma lipids
in humans.6 Subsequently, some studies have reported
that cinnamon extract decreases blood glucose,7 im-
proves glucose uptake in adipocytes,8 and improves the
function of pancreatic islets9 in Wistar rats, as well as
slowing down absorption of carbohydrates in the small
intestine.10 Cinnamon extract significantly increases in-
sulin sensitivity possibly by regulating the peroxisome
proliferator-activated receptor (PPAR)-medicated me-
tabolism of glucose and lipids11 as well as increasing the
amount of proteins involved in insulin signaling, glu-
cose transport, and anti-inflammatory/anti-angiogene-
sis responses.11,12
The active compounds of cinnamon have been report-
ed. These include water-soluble polyphenol type-A
polymers,8,11,13 cinnamaldehyde (CA)14-17 and procyani-
din oligomers.18 As a major and effective compound
isolated from cinnamon,19,20 CA possesses anti-hypogly-
cemic and anti-hypolipidemic effects in streptozotocin
(STZ)-induced T2DM in rats14,17 and improves the
function of pancreatic islets.9 However, reports on the
effect of CA on the metabolism of glucose and lipids in
T2DM are lacking. The aim of the present study was
to investigate the effect of CA in db/db mice, which
are used as models of obesity, insulin resistance and
T2DM.
METHODS
Ethical approval of the study protocol
The experimental protocols were approved by the Ani-
mal Care and Use Committee of Beijing University of
Chinese Medicine (Beijing, China).
Animals
Sixteen 7-week-old male BKS. Cg-+ Leprdb/+ Leprdb/
Jcl (db/db) mice and 8 non-diabetic littermate control
mice (db/+ ) were supplied by the Model Animal Re-
source Center of Nanjing University (Nanjing, China).
The animals were kept in the air-conditioned Animal
House of the Beijing University of Chinese Medicine
at 25°C-30°C and 45%-55% relative humidity. They
were fed standard food (Beijing Ke Ao Xie Li, Beijing,
China) ad libitum under a 12 h light-dark cycle
throughout the study.
Oral administration
After being fed for 1 week, 16 db/db mice were divid-
ed into two equal groups: CA and control. Mice in the
CA group received CA solution (0.5% dimethyl sulfox-
ide (DMSO), 20 mg·kg– 1·day– 1; Shanghai Winherb
Medical Science, Shanghai, China). Mice in the db/+
group and control group were given an equivalent vol-
ume of pure water alone (0.5% DMSO) by intragastric
administration once a day for 4 weeks. The CA dosage
was chosen based on that used in three reports.10,14,17
Measurement of FBG, serum insulin, HOMA-IR,
blood lipids and body weight
FBG was measured immediately with a Glucometer
(ACC U-Check; Roche, Basel, Switzerland) in tail-vein
blood (≈5 μL each time) after fasting for 8 h on days
7, 14, 21 and 28. After treatment for 4 weeks, mice
were fasted overnight and anesthetized with pentobar-
bital sodium (50 mg/kg, i.p.). Blood was collected
from the abdominal aorta. Serum levels of insulin were
assayed with an enzyme-linked immunoassay (ELISA)
kit (Linco Research, St Charles, MO, USA). Indices of
insulin resistance were calculated using the homeostasis
model of insulin resistance (HOMA-IR) index21 where-
by:
HOMA-IR=fasting blood glucose level (mmol/L) × se-
rum insulin level (ng/mL)/22.5
Serum levels of triglyceride (TG), total cholesterol
(TC), low-density lipoprotein-cholesterol (LDL-C),
high-density lipoprotein-cholesterol (HDL-C) and free
fatty acids (FFAs) were measured using commercial
kits (Beijing North Institute of Biological Technology,
Beijing, China) with an Automatic Biochemical Ana-
lyzer (AU400 Biochemistry Analyzer, Olympus, Tokyo,
Japan). Body weight was measured on days 7, 14, 21
and 28.
Preparation of total RNA
Frozen samples of quadriceps muscle and epididymal
fat tissues were crushed in liquid nitrogen. Total RNA
was extracted using Trizol reagent (Invitrogen, Carls-
bad, CA, USA). The relative purity of RNA was as-
sessed by spectrophotometric means. The ratio of ab-
sorbance at 260 nm to that at 280 nm was 1.7-2.0 for
all preparations. The integrity of RNA was confirmed
in 1% agarose gel.
mRNA analyses:
Total RNA was reverse-transcribed by a Reverse Trans-
fer kit (Beijing North Institute of Biological Technolo-
gy) with oligo dT primers following the manufacturer's
instructions. The sequences of sense and antisense
primers used for amplification are shown in Table 1.
GAPDH, glyceraldehyde 3-phosphate dehydrogenase;
TNF-α, tumor necrosis factor-α, GLUT4, glucose
transporter type 4.
Amplification was undertaken with an initial denatur-
ation at 95°C for 5 min followed by 30 cycles at 95°C
(30 s), 55°C (30 s), and then extension at 72°C (30 s).
The polymerase chain reaction (PCR) products were
separated on 1.0% agarose gel and stained with ethid-
ium bromide. Glucose transporter type 4 (GLUT4)
mRNAwas measured by denaturation at 95°C for 2 min
followed by 45 cycles of PCR (95°C for 20 s, 58°C for
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25 s and 72°C for 30 s). Relative RNA levels were de-
termined by analyzing the changes in SYBR green fluo-
rescence during PCR using the ΔΔCt method. To con-
firm amplification of specific transcripts, melting-curve
profiles were produced at the end of each reaction.
mRNA levels of all genes were normalized using glycer-
aldehyde 3-phosphate dehydrogenase (GAPDH) as the
internal control.
Table 1 Sequences of sense and antisense primers used for amplification
GAPDH (122 bp)
TNF-α (204 bp)
Adiponectin (149 bp)
GLUT4 (100 bp)
Sense
TGG AGA AAC CTG CCA AGT
CGT AGC AAA CCA CCA AGT G
CAT TAT GAC GGC AGC ACT G
GAG CCC CAG ATA CCT CTA CAT
CAT
Anti-sense
GTT GCT GTT GAA GTC GCA
ATA GCA AAT CGG CTG ACG
TCC TGA TAC TGGTCGTAG GTG
AGC TAG TGC GTC AGA CAC ATC
AGA
Western blotting
The extracted protein samples of muscle tissues were
separated on sodium dodecyl sulfate (SDS) polyacryl-
amide gels and electrotransferred onto polyvinylidene
difluoride (PVDF) membranes. PVDF membranes
were incubated with primary antibody (anti-Akt, an-
ti-phospho-Akt (Thr 308), anti-AMPKα and antiphos-
pho- AMPKα (Thr 172; Cell Signaling Technology,
Danvers, MA, USA). Detection of immunoreactive
bands was done using an Electrochemiluminescence
kit (Beijing North Institute of Biological Technology).
Densitometry was undertaken by scanning the radio-
graphs using the Image J 1.4.3 system (Media Cyber-
netics, Bethesda, MD, USA).
Statistical analyses
Statistical analyses were undertaken using SPSS
ver13.0 (SPSS, Chicago, IL, USA). Data are the mean±
standard deviation. Comparisons among the groups
were analyzed by one-way analysis of variance (ANO-
VA) followed by Dunnett's test. P<0.05 was consid-
ered significant.
RESULTS
Body weight
The changes in body weight after CA administration
for 4 weeks are shown in Figure 1 Body weight in the
db/+ group was significantly lower than that in the con-
trol and CA group during the 4-week treatment. Body
weight in the control group was higher than that in the
CA group on day 28 (P<0.05).
FBG levels
During the entire experiment, FBG levels in the con-
trol group and CA group were significantly higher that
those in the db/+ group (Figure 2). On day 28, FBG
levels in the CA group showed a significant reduction
compared with the control group.
Serm levels of TG, TC, HDL-C, LDL-C and FFAs
There were significant differences in all of the lipid lev-
els in the db/+ group compared with the control group
and CA group (both P<0.01) (Figure 3). Serum con-
centrations of HDL-C in the CA group increased sig-
nificantly as compared with the control group. Howev-
er, no statistically significant differences in the levels of
FFAs, TG, TC and LDL-C between the two groups
was noted (P=0.16, 0.58, 0.07 and 0.40, respectively).
Serum levels of insulin and the HOMA-IR index
Serum levels of insulin and the HOMA-IR index in
the CA group and control group were significantly
higher than those in the db/+ group (Figure 4), and sig-
nificant differences were observed between the CA
group and control group.
Changes in the mRNA expression of adiponectin and
tumor necrosis factor (TNF)-α in adipose tissue
Expression of adiponectin and TNF-α in white adi-
pose tissue is shown in Figure 5. TNF-α mRNA levels
in the CA group were significantly decreased as com-
pared with those in the control group. However, there
was no significant difference in adiponectin mRNA ex-
pression between the CA group and control group.
Changes in protein levels of Akt, p-Akt, AMPKα and
p-AMPKα as well as mRNA expression of GLUT4 in
muscle tissue
p-Akt protein expression and GLUT4 mRNA expres-
sion increased significantly in the CA group as com-
pared with the control group (both P<0.05) (Figure 6).
However, protein expression of Akt, p-AMPKα and
AMPKα did not significantly change in the CA group
as comparedwith the control group.
DISCUSSION
When genetic obesity is produced by complete knock-
out of the leptin receptor via the db mutation, db/db
mice develop severe resistance to insulin, resulting in se-
vere hyperglycemia and, ultimately, premature death
due to insufficient insulin action. 23 In the KS genetic
background, hyperglycemia secondary to severe obesi-
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Figure 2 Effects of CA on fasting blood glucose levels during 4-week treatment
Control group and CA group compared with the db/+ group, aP<0.001; on day 28, the CA group compared with the control
group, bP<0.05.
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Figure 3 Serum levels of lipids and FFAs in the treatment groups
Compared with the db/+ group bP<0.01; compared with the control group, cP<0.05.
梵蒂冈的和
c
a
b
c
b
b
Figure 4 Effects of CA on serum levels of insulin and the HOMA-IR index
aP<0.05, bP<0.01 vs. the db/+ group; cP<0.05 vs. the control group.
ba
a a
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Figure 1 Effects of CA on body weight during 4-week treatment
CA group and control group compared with the db/+ group, aP<0.001; on day 28, the CA group compared with the control group,
bP<0.05.
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ty-induced insulin resistance worsens with increase in
age.23 This particular inbred strain is an ideal model to
investigate the effect of CA on glucose metabolism and
insulin resistance in T2DM.
The results of the present study clearly showed that CA
produced a mild hypoglycemic effect after 4-week treat-
ment in mice. More importantly, CA treatment signifi-
cantly decreased the body weight, serum insulin level
and HOMA-IR index along with improvement in se-
rum levels of HDL-C. The anti-diabetic effect of CA
in db/db mice may be due to an improvement in insu-
lin sensitivity and loss of body weight. These results
suggest that CA has mild hypoglycemic and hypolipid-
emic effects in obesity and insulin resistance, in con-
trast to findings from previous reports.14
Insulin resistance is a major factor in the pathogenesis
of T2DM. It is induced primarily by decreases in the
insulin stimulation of glucose transport and metabo-
lism in muscles and adipocytes.24,25 Insulin-stimulated
glucose transport is known to occur through transloca-
tion of GLUT4 from the intracellular pool to the plas-
ma membrane. Signaling downstream of PI3-kinase
(PI3K) to GLUT4 translocation appears to be mediat-
ed (at least in part) by serine/threonine protein kinase B
(PKB/Akt)26 which is activated by phosphorylation at
Thr308 residues.27 In db/db mice, glucose utilization
in skeletal muscle decreases significantly due to major
defects in the activities of PI3K, PKB/Akt as well as
atypical protein kinase C (aPKC) activation accompa-
nied by a significant reduction in GLUT-4 mRNA ex-
pression in the quadriceps muscle.28,29 Although we did
not observe insulin-stimulated Akt kinase activity or
GLUT4 translocation, increases in the mRNA expres-
sion of GLUT4 and protein expression of p-Akt(Thr
308) in skeletal muscle suggested that the anti-diabetic
effects of CA could be achieved by influencing the
stimulation and translocation of GLUT4 in insulin-re-
sistant skeletal muscle. These results may be consistent
with those of Anand et al., which showed that CA re-
sults in the translocation of membrane GLUT4 in skel-
etal muscle after 60-day treatment in STZ-induced
T2DM in rats.17
The adenosine monophosphate-activated protein ki-
nase (AMPK) pathway plays an important part in regu-
lation of the metabolism of lipids and glucose. In addi-
tion, AMPK promotes glucose uptake into skeletal
muscle and suppresses glucose output from the liver
via insulin-independent mechanisms.30 In our previous
study, western blotting analyses showed that the level
of phosphorylated AMPK (Tyr172)31 in the skeletal
muscle of db/db mice was significantly lower than that
in db/+ mice, and was not significantly enhanced by
CA treatment. It has been suggested that CA may not
increase AMPK activity in insulin-resistant muscles.
Adipose tissue is increasingly recognized as an active en-
docrine organ with many secretory products and to be
part of the innate immune system. With obesity, mac-
rophages infiltrate adipose tissue, and numerous adipo-
cytokines are released by macrophages and adipo-
cytes.32 Adipocytokines have important roles in the
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Figure 6 Effects of CA on protein expressions of Akt, p-Akt, AMPKα and p-AMPKα and mRNA of GLUT4 in skeletal muscle tissue
aP<0.05, bP<0.01 vs the db/+ group; cP<0.05 vs the control group.
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Figure 5 Effects of CA on mRNA expressions of adiponectin and TNF-α in adipose tissue
aP<0.01 vs. the db/+ group; bP<0.05 vs. the control group.
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pathogenesis of insulin resistance and associated meta-
bolic complications such as dyslipidemia, hyperten-
sion, and premature heart disease. In addition to the
production of pro-inflammatory cytokines that pro-
mote metabolic complications, adipose tissue is the
sole source of adiponectin, which has anti-inflammato-
ry actions and is associated with atherosclerosis.33,34 Cir-
culating levels of FFAs are increased in obesity and can
induce insulin resistance.35 The present study showed
that CA decreased the expression of TNF-α in adipose
tissue and serum levels of FFAs, which are possibly in-
duced by a loss in body weight, but CA acts as an "in-
sulin sensitizer" according to our analysis on the tran-
scriptional level of PPARs (manuscript in preparation).
This was the first study to explore the effects and mech-
anisms of CA on an obesity and insulin-resistance mod-
el of T2DM. This is in contrast to a STZ-induced
model of T2DM, which is characterized by beta-cell
damage.36 In conclusion, CA exhibited hypoglycemic
and hypolipidemic effects in db/db mice along with
loss in body weight. This investigation revealed the po-
tential use of CA or cinnamon as a natural alternative
treatment for T2DM and/or metabolic syndrome.
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